Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

A Three-Dimensional In Vitro Coculture Model to Quantify Breast Epithelial Cell Adhesion to Endothelial Cells.

Swaminathan S, Cranston AN, Clyne AM.

Tissue Eng Part C Methods. 2019 Oct;25(10):609-618. doi: 10.1089/ten.TEC.2019.0122. Epub 2019 Sep 26.

PMID:
31441384
2.

Body composition in long-term survivors of acute lymphoblastic leukemia diagnosed in childhood and adolescence: A focus on sarcopenic obesity.

Marriott CJC, Beaumont LF, Farncombe TH, Cranston AN, Athale UH, Yakemchuk VN, Webber CE, Barr RD.

Cancer. 2018 Mar 15;124(6):1225-1231. doi: 10.1002/cncr.31191. Epub 2017 Dec 12.

3.

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.

Oplustil O'Connor L, Rulten SL, Cranston AN, Odedra R, Brown H, Jaspers JE, Jones L, Knights C, Evers B, Ting A, Bradbury RH, Pajic M, Rottenberg S, Jonkers J, Rudge D, Martin NM, Caldecott KW, Lau A, O'Connor MJ.

Cancer Res. 2016 Oct 15;76(20):6084-6094. Epub 2016 Aug 22.

4.

Clinical development of new drug-radiotherapy combinations.

Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR; NCRI CTRad Academia-Pharma Joint Working Group.

Nat Rev Clin Oncol. 2016 Oct;13(10):627-42. doi: 10.1038/nrclinonc.2016.79. Epub 2016 Jun 1.

5.

Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.

Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O'Connor MJ, Huntsman DG, Wang Y, Gilks CB.

Clin Cancer Res. 2011 Feb 15;17(4):783-91. doi: 10.1158/1078-0432.CCR-10-1382. Epub 2010 Nov 19.

6.

RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B.

Cranston AN, Carniti C, Oakhill K, Radzio-Andzelm E, Stone EA, McCallion AS, Hodgson S, Clarke S, Mondellini P, Leyland J, Pierotti MA, Whittaker J, Taylor SS, Bongarzone I, Ponder BA.

Cancer Res. 2006 Oct 15;66(20):10179-87.

7.

The Ret(C620R) mutation affects renal and enteric development in a mouse model of Hirschsprung's disease.

Carniti C, Belluco S, Riccardi E, Cranston AN, Mondellini P, Ponder BA, Scanziani E, Pierotti MA, Bongarzone I.

Am J Pathol. 2006 Apr;168(4):1262-75.

8.

Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection.

Böckmann M, Hilken G, Schmidt A, Cranston AN, Tannapfel A, Drosten M, Frilling A, Ponder BA, Pützer BM.

Hum Gene Ther. 2005 Nov;16(11):1267-75.

PMID:
16259560
9.

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN, Dahmen U, Ponder BA, Pützer BM.

J Natl Cancer Inst. 2004 Aug 18;96(16):1231-9.

PMID:
15316058
11.

Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors.

Russell SE, McIlhatton MA, Burrows JF, Donaghy PG, Chanduloy S, Petty EM, Kalikin LM, Church SW, McIlroy S, Harkin DP, Keilty GW, Cranston AN, Weissenbach J, Hickey I, Johnston PG.

Cancer Res. 2000 Sep 1;60(17):4729-34.

Supplemental Content

Loading ...
Support Center